Literature DB >> 12144576

Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy.

P Della Monica1, A Lavagna, G Masoero, L Lombardo, L Crocellá, A Pera.   

Abstract

AIM: To evaluate the choice and relative effectiveness of Helicobacter pylori eradication regimens in a primary care setting. PATIENTS AND METHODS: Patients referred to our department, who had been treated for H. pylori infection during the preceding 6 months, were enrolled between September 1998 and July 1999. H. pylori status was assessed by urea breath test. Information on the drugs administered, compliance and side-effects was recorded.
RESULTS: The mean eradication rate was 72% in patients receiving their first course of treatment (1863 cases; 45% male; mean age, 53 +/- 14 years); a double therapy regimen was prescribed to 14% of patients, triple therapy to 85% and quadruple therapy to 1%. Maastricht Consensus proton pump inhibitor-based regimens were prescribed in 80% of cases, with a mean eradication rate of 73%. No statistically significant correlation was found between eradication failure and sex, age, endoscopic findings or administered treatment.
CONCLUSIONS: In Italy, in a primary care setting, first-line H. pylori eradication therapies reflect international guidelines. The efficacy of such regimens is lower than that reported by controlled trials. These results are relevant when making pharmacoeconomic evaluations of H. pylori management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12144576     DOI: 10.1046/j.1365-2036.2002.01244.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  21 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

2.  It is time to rethink H. pylori therapy.

Authors:  Bich N Dang; David Y Graham
Journal:  J Gastrointestin Liver Dis       Date:  2017-06       Impact factor: 2.008

Review 3.  One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm.

Authors:  David Y Graham; Yoshio Yamaoka
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

Review 4.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

5.  Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.

Authors:  Xiao-Zhong Gao; Xiu-Li Qiao; Wen-Chong Song; Xiao-Feng Wang; Feng Liu
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

6.  Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial.

Authors:  Josip Bago; Karolina Majstorović; Zeljka Belosić-Halle; Nastja Kućisec; Vinko Bakula; Monika Tomić; Petra Bago; Rosana Troskot
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-04-15       Impact factor: 3.944

7.  In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori.

Authors:  Morris O Makobongo; Tchelet Kovachi; Hanan Gancz; Amram Mor; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

8.  Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.

Authors:  Giuseppe Scaccianoce; Cesare Hassan; Alba Panarese; Donato Piglionica; Sergio Morini; Angelo Zullo
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

Review 9.  The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis.

Authors:  Angelo Zullo; Vincenzo De Francesco; Cesare Hassan; Sergio Morini; Dino Vaira
Journal:  Gut       Date:  2007-06-12       Impact factor: 23.059

10.  Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond.

Authors:  David Y Graham; Hong Lu; Yoshio Yamaoka
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.